India’s largest drugmakers want the U.S. to import their drugs to hold down healthcare costs. But questions on manufacturing quality are clouding their efforts.
Novartis is still facing fallout from last year’s kickbacks case in South Korea. Officials there levied a set of punishments and are weighing "tougher…
Masking depression is never a good idea. Otsuka and Lundbeck are back on the air to make that case with a new TV ad for antipsychotic Rexulti.
China has updated its list of medicines covered by national medical insurance, adding some new drugs in pediatrics and major illnesses such as cancer and…
Welcome to the price-pledge club, Takeda. The Japanese drugmaker has said it plans to keep its price increases in the single digits.
Takeda says its new oral multiple myeloma drug Ninlaro is on course to become its biggest-ever cancer product.
Daiichi Sankyo licenses two abuse-deterrent painkillers from Inspirion to further its pain-management ambitions.
The roll-out of Samsung Bioepis' biosimilar version of blockbuster immunology drug Enbrel is going so well that analysts think additional manufacturing…
The PD-1 inhibitor patent battle raging between Merck and Bristol-Myers Squibb in the U.S., Europe and Australia has now reached Japan.
Another disciple of Valeant and its price-hiking credo is bidding farewell to its CEO.